Evidence map›Paper›PMID 41121394›Full record

ArticleMicrobiome2025

Megasphaera contributes to lactate-driven valerate production in the human gut.

Lucía Huertas-Díaz, Mensure Elvan Gezer, Angeliki Marietou, Jiri Hosek, Line Thams, Line Barner Dalgaard, Mette Hansen, Clarissa Schwab

Abstract read
In one paragraph

Article in Microbiome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Frontiers in microbiology · 2026
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lucía Huertas-DíazDepartment of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.
Mensure Elvan GezerDepartment of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.
Angeliki MarietouDepartment of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.
Jiri HosekDepartment of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.
Line ThamsDepartment of Public Health, Aarhus University, Aarhus, Denmark.
Line Barner DalgaardDepartment of Public Health, Aarhus University, Aarhus, Denmark.
Mette HansenDepartment of Public Health, Aarhus University, Aarhus, Denmark.
Clarissa SchwabDepartment of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark. schwab@bce.au.dk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe human gut microbiota produces short-chain carboxylic acids (SCCA) through fermentation of undigested carbohydrates, and through chain elongation, a process that can be modulated through diet. Valerate is frequently recovered from human fecal samples, but little is known about dietary components, microbial contributors, and cross-feeding interactions that drive human intestinal valerate formation. We combined co-culture studies and in vitro human fecal microbiota batch fermentations (n = 20) with the analysis of a free-living cohort of obese and overweight women (n = 49) that monitored and modified (fermented) dairy consumption, to study the role of dairy-derived lactose and lactate in intestinal microbial formation of valerate.

resultsWhile the valerate producer Megasphaera elsdenii was not able to use lactose in single culture, valerate was formed (6.2 ± 1.3 mM) in co-culture with the lactose-utilizing and lactate-producing food microbe Streptococcus thermophilus. In vitro, valerate was produced by fecal microbiota of most donors (15/20) in control medium. Lactose addition significantly (p < 0.05) increased valerate formation of fecal microbiota that harbored Megasphaera at levels ≥ 5 log cells/mL (n = 4), while valerate formation was lower when Megasphaera was less abundant or not detected (n = 15). The addition of M. elsdenii to batch fermentations increased valerate production in 80% of samples and correlation analysis showed a positive correlation (p < 0.001) between relative abundance of Megasphaera and valerate levels. In vivo, 30% of study participants harbored Megasphaera based on 16S rRNA gene amplicon sequencing and species-specific qPCR. Diet supplementation with drained yogurt (skyr) led to higher fecal microbial diversity (p < 0.05) and relative abundance of Streptococcaceae. Participants that harbored Megasphaera and consumed skyr daily had significantly (p < 0.05) higher fecal valerate levels at week 6 compared to controls. In addition, fecal levels of lactate were higher in the skyr compared to the control group at 12 weeks. Linear discriminant analysis suggested co-occurrence of Megasphaera with the lactate-producer Lactobacillus and competition with other lactate utilizers such as the Anaerobutyricum hallii group.

conclusionThis study brings forward new mechanistic understanding on the intestinal microbial formation of the SCCA valerate. Our findings identified Megasphaera as an infrequently occurring and low abundant keystone taxon contributing to lactose/lactate-driven valerate production in overweight/obese women. Our results highlight that the presence of Megasphaera affects the fermentative response to daily consumption of fermented dairy. Video Abstract.

Indexed as

Gastrointestinal MicrobiomeLactic AcidMegasphaeraAdultCoculture TechniquesFecesFemaleFermentationHumansLactoseMiddle AgedObesityOverweightStreptococcus thermophilusLactic AcidLactoseCross-feedingLactateLactoseMegasphaeraValerate production

Identifiers

PMID41121394
PMCPMC12538753

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.